[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561047":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":42,"collaborators":7,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Shanghai Changzheng Hospital","OTHER",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","All enrolled subjects completed dynamic blood glucose monitoring to obtain continuous peripheral blood glucose data.",[13],{"name":14,"affiliation":5,"role":15},"tuo Li, Prof.","STUDY_DIRECTOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Tuo Li, Doctor","CONTACT","86-13918507887","dr.lituo@smmu.edu.cn",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Changzheng Hospital","RECRUITING","Shanghai","Shanghai Municipality","200003","China","CN",{"type":32,"coordinates":33},"Point",[34,35],121.45806,31.22222,{"lat":35,"lon":34},[38],{"name":39,"role":19,"phone":40,"phoneExt":7,"email":41},"tuo li","13918507887","zoe_leeto@hotmail.com",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Tuo Li, MD","Deputy Director","100561047",false,"NCT06585072","Pancreatic Cancer and Diabetes Mellitus","Prospective Cohort Study on Endo-Exdo Secretory Function Alterations and All-round Outcomes After Pancreatic Cancer","Inclusion Criteria:\n\n1\\. male or female Chinese subjects; 2. Age ≥ 18 years; 3. patients with pancreatic cancer who are proposed to undergo pancreatectomy by pancreaticobiliary surgery at our hospital; 4. those who voluntarily completed the Pancreatobiliary Surgery Cohort Study and signed the informed consent; 5. those who have completed and banked serum and pathological specimens at our hospital.\n\n\\-\n\nExclusion Criteria:\n\n1\\. those with a previous history of comorbid diabetes mellitus or pre-diabetes mellitus, or preoperative HbA1C ≥ 6.0% or fasting blood glucose ≥ 6.1 mmol\u002Fl; 2. those with positive islet-associated antibodies 3. those with the presence of medications, endocrine disease exposures that can lead to a risk of secondary diabetes; 4. pregnant or nursing women; 5. Cognitive impairment or other reasons for failing to sign the informed consent form.\n\n\\-","ALL","18 Years",{"count":55,"type":56},150,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about post-surgery of pancreatic cancer diabetes mellitus.The main questions it aims to answer are:\n\n1. Are the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) after pancreatic cancer of different etiologies the same?\n2. Are alterations in endocrine and exdocrine secretory function in patients with pancreatic surgery associated with all-round outcomes? All patients with pancreatic surgery have been given the standardized treatment for the condition.\n\nThe reasearchers will summarize the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) during different surgical procedures to explore the association between alternations in endocrine and exdocrine secrectory function and all-round outcomes.",[60,61,62],"Pancreatic Cancer","Surgery","Diabetes Mellitus",[60,61,62,64],"Risk factor","2025-06-26",{"date":67,"type":68},"2025-07-01","ACTUAL",{"date":70,"type":68},"2025-01-03",{"date":72,"type":56},"2026-09-01",{"name":5,"class":6},1]